ArticleWorld journal of transplantation2025
Dietary interventions
Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChylous ascites (CA), which is characterized by lymphatic leakage into the peritoneal cavity, is a rare but significant complication of liver transplantation. Although dietary and pharmacological strategies have shown effectiveness in managing CA, standardized treatment protocols have yet to be established.
aimTo evaluate the comparative effectiveness of low-fat diet (LFD) enriched with medium-chain triglycerides (MCTs)
methodsA comprehensive literature review was conducted to analyze the outcomes of dietary interventions and octreotide therapy. The key parameters examined included resolution rates, treatment duration, and recurrence.
resultsA comprehensive literature search yielded 13 studies that met the inclusion criteria, comprising 4 retrospective cohort studies and 8 case studies. The incidence of CA following liver transplantation ranges from 0.6% to 4.7%. The onset varied, with a median time to diagnosis of 10 days after transplantation. A LFD with MCT supplementation was used as the first-line therapy in 83.3% of the studies, with resolution rates ranging from 62.5% to 100%. Octreotide therapy was utilized in 66.7% of the studies, primarily as a second-line therapy, with resolution rates of 83.3% to 100%. Combination therapy showed a significantly higher resolution rate than did dietary management alone (97.8%
conclusionA stepwise approach to CA management is recommended, initiating dietary interventions and escalating to octreotide when necessary. Further research through well-designed randomized controlled trials is essential to establish standardized treatment protocols for optimizing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.